Latest Car T News

Chimeric Therapeutics reports encouraging Phase 1/2 data for its CHM CDH17 CAR-T therapy in advanced gastrointestinal cancers, with 82% of evaluable patients achieving stable disease and durable responses lasting over a year.

2 Cheap Cars Group held its ground in a challenging FY26, delivering a net profit after tax of $3.2 million amid rising carbon costs and softer vehicle sales, supported by a robust second-half recovery and record finance penetration.

Imugene has dosed the first patient in a new cohort combining its azer-cel CAR T therapy with BTK inhibitors, targeting patients with B-cell malignancies who failed prior BTKi treatment. This move broadens the trial’s scope and tackles a significant unmet need in blood cancer therapy.

Eagers Automotive delivered record $13 billion revenue and underlying EBITDAI of $620.9 million in 2025, boosted by strategic investments in CanadaOne Auto and Mitsubishi Corporation. The company’s 2026 outlook is positive, supported by strong order books and easing supply constraints.

AdAlta has engaged specialist advisors to streamline US FDA regulatory processes for its CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients.

Imugene Limited’s allogeneic CAR T therapy, azer-cel, delivered an 81% overall response rate in a Phase 1b trial cohort of CAR T-naïve patients with various CD19 B-cell malignancies, with updated data due at ASCO 2026.

Turners Automotive Group has posted a record $63.2 million normalised NPBT for FY26, advancing its $65 million NPBT target to FY27 and setting sights on $100 million by FY31 amid solid finance and retail momentum.

MyEco Group has extended its partnership with Penrith City Council by winning a 3-to-5-year contract to supply compostable caddy liners for the council's FOGO program, aligning with NSW's mandated organics recycling rollout.

Webjet Group reported a 1% revenue rise to $136.4 million for FY26 but saw underlying EBITDA drop 20% to $28.1 million due to increased investment and softer trading. The company completed its Locomote acquisition, announced a fully franked 4 cents per share dividend, and revealed CEO Katrina Barry’s resignation.

Plenti Group Limited (ASX:PLT) has smashed its $3 billion loan portfolio target two months ahead of schedule, delivering a 117% surge in cash profit before tax to $30.8 million for FY26. The fintech lender’s growth was fuelled by record loan originations, robust credit performance, and strategic technology investments.

Smartgroup posted robust 2025 results with record customer growth and accelerated EV leasing, backed by strategic digital investments and a $20 million share buy-back plan following fleet portfolio sales.

Arovella Therapeutics has named Dr Nicole Van Der Weerden as acting CEO following Dr Michael Baker’s departure, positioning her to steer the company through the critical phase I trial of its CAR-iNKT therapy ALA-101.